Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Completed · Phase 1

Conditions studied: Hodgkin's Lymphoma

In brief

The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.

Key facts

Study ID

NCT02164006

Run by

TG Therapeutics, Inc.

People needed

16

Starts

2014-06-11

Expected to finish

2016-05-01

Last updated by the study team

2019-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of Hodgkin's Lymphoma
• Relapsed or refractory after an autologous stem cell transplant (ASCT) or at least two prior multi-agent chemotherapy regimens in patients not candidates for ASCT
• Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

You may not qualify if…

• Any major surgery, chemotherapy or immunotherapy within the last 21 days
• Known hepatitis B virus, hepatitis C virus or HIV infection
• Autologous hematologic stem cell transplant within 3 months of study entry. Patients who had prior Allogeneic hematologic stem cell transplant are excluded

Where it is running

• TG Therapeutics Investigational Trial Site — Duarte, California, United States
• TG Therapeutics Investigational Trial Site — San Diego, California, United States
• TG Therapeutics Investigational Trial Site — Sarasota, Florida, United States
• TG Therapeutics Investigational Trial Site — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.